Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Praluent Pricing: Collaboration With ICER Sets A New Standard

Executive Summary

Sanofi/Regeneron reveal plans to lower price of PCSK9 blocker Praluent to match ICER's updated recommendation, following assessment based on new outcomes data. Decision sparks debate across industry and raises questions about setting precedent on pricing for the future.


Related Content

PCSK9 Turning Point? Sanofi/Regeneron Dangle Lower Price Carrot For Praluent
The Price Is Right: Amgen Defends Repatha At $9,669 Against More Critics
PCSK9 Sales Still Slow, But May Get Boost From Label, Guideline Changes
Repatha Pricing Pressure Might Actually Increase After Outcomes Trial
Sanofi, Regeneron Setting 'New Paradigm' With Dupixent Pricing In US?
Amgen Says Repatha Outcomes Trial Backs Up Its Pricing Math


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts